Sign In
Buy HCM
$9.99
-0.290 (-2.82%)
At Close: Jun 22, 2026
Hutchison China MediTech Limited 2020 Q2 - Results - Earnings Call Presentation
11:22am, Thursday, 30'th Jul 2020
The following slide deck was published by Hutchison China MediTech Limited in conjunction with their 2020 Q2 earnings call.
Chi-Med’s NDA for Savolitinib in Non-Small Cell Lung Cancer Granted Priority Review in China
06:00am, Tuesday, 28'th Jul 2020
HONG KONG and FLORHAM PARK, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announced that the China National Medical Products Administ
Week In Review: BeiGene Signs $540 Million Deal For China Rights To 3 HBV Candidates
12:07pm, Sunday, 26'th Jul 2020
Beijing's BeiGene in-licensed Greater China rights to three inhibitors for chronic hepatitis B virus from Assembly Biosciences in a $540 million agreement.
Chi-Med Initiates a Phase I Trial of IDH1/2 Dual Inhibitor in Patients with Hematological Malignancies in China
06:00am, Friday, 24'th Jul 2020
— HMPL-306 is the ninth innovative oncology drug candidate discovered in house by Chi-Med —HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 24, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTec
Did Business Growth Power Hutchison China MediTech's (LON:HCM) Share Price Gain of 162%?
07:11am, Wednesday, 22'nd Jul 2020
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
Edison Issues ADR Outlook on Hutchison China MediTech (HCM)
04:55pm, Monday, 06'th Jul 2020
LONDON, UK / ACCESSWIRE / July 6, 2020 / Hutchison China MediTech (NASDAQ:HCM) is on the brink of global launches of two assets from its internally developed oncology portfolio. In 2022 we expect US l
Week In Review: VistaGen Out-Licenses China/Asia Rights For Novel Anxiety Drug To EverInsight In $177 Million Deal
11:34am, Sunday, 28'th Jun 2020
VistaGen of South San Francisco out-licensed China/Southeast Asia rights for a novel anxiety treatment to EverInsight Therapeutics, a China in-licensing company
Chi-Med to Announce 2020 Half-Year Financial Results
06:00am, Friday, 26'th Jun 2020
LONDON, June 26, 2020 -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) will be announcing its interim results for the six months ended June 30, 2020 on.
The following is a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) * ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD
Chi-Med Announces US$100 Million Equity Investment by General Atlantic
06:15am, Thursday, 25'th Jun 2020
Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (Nasdaq/AIM: HCM) today announces that it has entered into a definitive agreement for the sale of US$100 million of shares at a pr
Chi-Med Announces Fruquintinib Granted U.S. FDA Fast Track Designation for Metastatic Colorectal Cancer
07:15am, Thursday, 18'th Jun 2020
LONDON, June 18, 2020 -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the U.S. Food and Drug Administration (“FDA”) has granted Fast.
Is Hutchison China MediTech Limited (HCM) A Good Stock To Buy?
05:03pm, Friday, 12'th Jun 2020
In this article we will take a look at whether hedge funds think Hutchison China MediTech Limited (NASDAQ:HCM) is a good investment right now. We check hedge fund and billionaire investor sentiment be
Chi-Med Announces US$95 million Guangzhou Land Compensation Agreement
06:00am, Tuesday, 09'th Jun 2020
LONDON, June 09, 2020 -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company.
Based on the preset criteria, the IDMC recommended that the trial continue. FRUTIGA is a Phase III trial in China of fruquintinib in combination with paclitaxel (Taxol®) in the treatment of patients
Chi-Med Plans to Submit NDA for Surufatinib Following Pre-NDA Meeting with the U.S. FDA
06:00am, Monday, 01'st Jun 2020
LONDON, June 01, 2020 -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that it has held its pre-New Drug Application (“NDA”) meeting with the.
